08:30 AM EDT, 07/14/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Monday that it has filed a New Drug Application with the US Food and Drug Administration for its selective cortisol modulator relacorilant to treat patients with platinum-resistant ovarian cancer.

The filing is based on the results of the treatment's pivotal late-stage and mid-stage trials, which showed that patients who have received relacorilant plus nab-paclitaxel had better progression-free and overall survival than patients who received nab-paclitaxel alone, the company said.

Corcept chief executive officer Joseph Belanoff said the company is working to make the drug "available immediately" after regulatory approval.